Dysregulated CC receptor/ligand in monocytes/macrophages from tongue squamous cell carcinoma patients is partially rectified by interferon α-2b

Human Immunology

Volumn 73, Issue 1, 2012, Pages 38-47

  Chakraborty, Krishnendu ^a,b   Bose, Anamika ^a,c   Goswami, Kuntal K ^a   Mukherjee, Kalyan K ^a   Goswami, Shyamal ^a   Ghosh, Diptendu ^a   Chakraborty, Tathagata ^a   Sarkar, Koustav ^a,d   Pal, Smarajit ^a   Bhowmick, Anup ^a   Biswas, Jaydip ^a   Baral, Rathindranath ^a  

^a CHITTARANJAN NATIONAL CANCER INSTITUTE   (India)

^b LOUISIANA STATE UNIVERSITY   (United States)

^c BOSE INSTITUTE   (India)

^d CHILDREN S HOSPITAL OF PITTSBURGH   (United States)

Author keywords

CCR5; Chemokines; IFN 2b; Macrophages; Monocytes; Tongue squamous cell carcinoma

Indexed keywords

CHEMOKINE RECEPTOR CCR5; CISPLATIN; FLUOROURACIL; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; RANTES; RECOMBINANT ALPHA2B INTERFERON; SHANFERON; UNCLASSIFIED DRUG;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER PATIENT; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; FEMALE; HUMAN; HUMAN CELL; IMMUNOMODULATION; IN VITRO STUDY; LYMPHOCYTE FUNCTION; LYMPHOCYTE PROLIFERATION; MACROPHAGE; MACROPHAGE FUNCTION; MACROPHAGE MIGRATION; MALE; MONOCYTE; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; PROTEIN EXPRESSION; SQUAMOUS CELL CARCINOMA; T LYMPHOCYTE; TONGUE CARCINOMA; TONGUE SQUAMOUS CELL CARCINOMA; TREATMENT OUTCOME; UPREGULATION;

ADULT; AGED; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; CELL MOVEMENT; CELLS, CULTURED; CHEMOKINE CCL3; CHEMOKINE CCL4; CHEMOKINE CCL5; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INTERFERON-ALPHA; LIGANDS; MACROPHAGES; MALE; MIDDLE AGED; MONOCYTES; RECEPTORS, CCR5; RECOMBINANT PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TONGUE NEOPLASMS; TREATMENT OUTCOME; U937 CELLS;

EID: 84355161983     PISSN: 01988859     EISSN: 18791166     Source Type: Journal    
DOI: 10.1016/j.humimm.2011.10.015     Document Type: Article

References (29)

1. Gemenetzidis E., Bose A., Riaz A.M., et al. FOXM1 upregulation is an early event in human squamous cell carcinoma and it is enhanced by nicotine during malignant transformation. PLoS ONE 2009, 4:e4849.
2. Murdoch D. Standard, and novel cytotoxic and molecular-targeted, therapies for HNSCC: an evidence-based review. Curr Opin Oncol 2007, 19:216-221.
3. Bhattacharya N., Roy A., Roy B., Roychoudhury S., Panda C.K. MYC gene amplification reveals clinical association with head and neck squamous cell carcinoma in Indian patients. J Oral Pathol Med 2009, 38:759-763.
4. van der Schroeff M.P., van Schie K., Langeveld T.P., Looman C., Baatenburg de Jong R.J. Model-assisted predictions on prognosis in HNSCC: do we learn?. Eur Arch Otorhinolaryngol 2010, 267:1445-1448.
5. Rapidis A.D., Wolf G.T. Immunotherapy of head and neck cancer: current and future considerations. J Oncol 2009, 346345.
6. Wolf G.T. Tradition, teamwork, and tailored treatment: surgical oncology in the genomic era. Arch Otolaryngol Head Neck Surg 2009, 135:337-341.
7. Belardelli F., Ferrantini M., Proietti E., Kirkwood J.M. Interferon-alpha in tumor immunity and immunotherapy. Cytokine Growth Factor Rev 2002, 13:119-134.
8. Ferrantini M., Capone I., Belardelli F. Interferon-alpha and cancer: mechanisms of action and new perspective of clinical use. Biochimie 2007, 89:884-893.
9. Yurkovetsky Z.R., Kirkwood J.M., Edington H.D., Marrangonil A.M., Velikokhatnaya L., Winans M.T. Multiplex analysis of serum cytokines in melanoma patients treated with IFN-{alpha} 2b. Clin Cancer Res 2007, 13:2422-2428.
10. Ravaud A., Trufflandier N., Ferrière J.M., Debled M., Palussière J., Cany L., et al. Subcutaneous interleukin-2, interferon alpha-2b and 5-fluorouracil in metastatic renal cell carcinoma as second line treatment after failure of previous immunotherapy: a phase II trial. Br J Cancer 2003, 89:2213-2218.
11. Bose A., Chakraborty T., Chakraborty K., Pal S., Baral R. Dysregulation in immune functions is reflected in tumor cell cytotoxicity by peripheral blood mononuclear cells from head and neck squamous cell carcinoma patients. Cancer Immun 2008, 8:10.
12. Bose A., Ghosh D., Pal S., Mukherjee K.K., Biswas J., Baral R. Interferon alpha2b augments suppressed immune functions in tobacco-related head and neck squamous cell carcinoma patients by modulating cytokine signaling. Oral Oncol 2006, 42:161-171.
13. Bose A., Baral R.N. IFNα2b stimulated release of IFNγ differentially regulates T cell and NK cell mediated tumor cell cytotoxicity. Immunol Lett 2007, 108:68-77.
14. Mukherjee KK, Bose A, Ghosh D, Sarkar K, Goswami S, Pal S, et al. IFNa2b augments immune responses of cisplatin+5-fluorouracil treated tongue squamous cell carcinoma patients. Indian J Med Res in press.
15. Murdoch C., Muthana M., Coffelt S.B., Lewis C.E. The role of myeloid cells in the promotion of tumour angiogenesis. Nat Rev Cancer 2008, 8:618-631.
16. Markham R.B., Pier G.B., Goellner J.J., Mizel S.B. In vitro T cell-mediated killing of Pseudomonas aeruginosa. II. The role of macrophages and T cell subsets in T cell killing. J Immunol 1985, 134:4112-4117.
17. Strieter R.M., Belperio J.A., Phillips R.J., Keane M.P. CXC chemokines in angiogenesis of cancer. Semin Cancer Biol 2004, 14:195-200.
18. Sallusto F., Lanzavecchia A., Mackay C.R. Chemokines and chemokines receptors in T-cell priming and Th1/Th2-mediated responses. Immunol Today 1998, 19:568-574.
19. Chakraborty K., Bose A., Pal S., Chattopadhyay U., Baral R. Interferon alpha2b restores the impaired chemotactic activity of peripheral blood mononuclear cells from head and neck squamous cell carcinoma patients by modulating CXC receptor ligand interaction. J Interferon Cytokine Res 2008, 28:487-499.
20. Giri R.K., Rajagopal V., Shahi S., Zlokovic B.V., Kalra V.K. Mechanism of amyloid peptide induced CCR5 expression in monocytes and its inhibition by siRNA for Egr-1. Am J Physiol Cell Physiol 2005, 289:C264-C276.
21. Samson M., Labbe O., Mollereau C., Vassart G., Parmentier M. Molecular cloning and functional expression of a new human CC-chemokine receptor gene. Biochemistry 1996, 35:3362-3367.
22. Qin S., Rottman J.B., Myers P., Kassam N., Weinblatt M., Loetscher M., et al. The chemokine receptors CXCR3 and CCR5 mark subsets of T cells associated with certain inflammatory reactions. J Clin Invest 1998, 101:746-754.
23. Schall T.J., Bacon K., Toy K.J., Goeddel D.V. Selective attraction of monocytes and T lymphocytes of the memory phenotype by cytokine RANTES. Nature 1990, 347:669-671.
24. Lang S., Lauffer L., Clausen C., Löhr I., Schmitt B., Hölzel D., et al. Impaired monocyte function in cancer patients: restoration with a cyclooxygenase-2 inhibitor. FASEB J 2003, 17:286-288.
25. Dehmel S., Wang S., Schmidt C., Kiss E., Loewe R.P., Chilla S., et al. Chemokine receptor Ccr5 deficiency induces alternative macrophage activation and improves long-term renal allograft outcome. Eur J Immunol 2010, 40:267-278.
26. Mantovani A., Sica A., Locati M. Macrophage polarization comes of age. Immunity 2005, 23:344-346.
27. Trapani J.A., Smyth M.J. Functional significance of the perforin/granzyme cell death pathway. Nat Rev Immunol 2002, 2:735-747.
28. Gordon S. Alternative activation of macrophages. Nat Rev Immunol 2003, 3:23-35.
29. Mantovani A., Sica A., Sozzani S., Allavena P., Vecchi A., Locati M. The chemokine system in diverse forms of macrophage activation and polarization. Trends Immunol 2004, 25:677-686.